1. Home
  2. EVTC vs KOD Comparison

EVTC vs KOD Comparison

Compare EVTC & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evertec Inc.

EVTC

Evertec Inc.

HOLD

Current Price

$27.79

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Kodiak Sciences Inc

KOD

Kodiak Sciences Inc

HOLD

Current Price

$32.05

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVTC
KOD
Founded
1988
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.3B
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
EVTC
KOD
Price
$27.79
$32.05
Analyst Decision
Hold
Buy
Analyst Count
5
7
Target Price
$35.80
$35.43
AVG Volume (30 Days)
341.8K
557.3K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
0.67%
N/A
EPS Growth
27.17
N/A
EPS
0.47
N/A
Revenue
$453,869,000.00
N/A
Revenue This Year
$12.68
N/A
Revenue Next Year
$6.86
N/A
P/E Ratio
$60.04
N/A
Revenue Growth
11.48
N/A
52 Week Low
$21.81
$9.80
52 Week High
$34.77
$47.84

Technical Indicators

Market Signals
Indicator
EVTC
KOD
Relative Strength Index (RSI) 37.14 28.41
Support Level $27.64 $29.21
Resistance Level $30.40 $45.23
Average True Range (ATR) 0.93 1.52
MACD -0.20 -0.26
Stochastic Oscillator 4.44 8.50

Price Performance

Historical Comparison
EVTC
KOD

About EVTC Evertec Inc.

Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Share on Social Networks: